Entera Bio Ltd (ENTX) FinancialsENTXFinancialEntera Bio Ltd

Evaluating the bottom line, Entera Bio Ltd maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -138.92%, provide a clear picture of how effectively ENTX converts its operational activities into shareholder value.

In the context of the broader market, ENTX competes directly with industry leaders such as OVID and CAPR. With a market capitalization of $524.62M, it holds a significant position in the sector. When comparing efficiency, ENTX's gross margin of N/A stands against OVID's 100.00% and CAPR's N/A. Such benchmarking helps identify whether Entera Bio Ltd is trading at a premium or discount relative to its financial performance.

Entera Bio has shown significant revenue fluctuations, with total revenue of $42,000 in Q3 2024 and $82,000 in Q4 2024, but has reported net losses consistently, with a net loss of $7.31 million in Q2 2026, indicating ongoing financial strain. The current ratio remains strong at 8.98, suggesting good short-term liquidity.